ASS DEV.TECH.ADMIN.MEDICAMENT.CONTINUE
ADTAMC
ASS DEV.TECH.ADMIN.MEDICAMENT.CONTINUE is a company registered under SIREN number 433509940, with its registered office in MONTPELLIER. Its main activity falls under the sector: Scientific research and development. It has 2 establishments.
Sources: INSEE Sirene.
Identity
- Legal form
- Declared association
- Activity
- Other research and experimental development on natural sciences and engineering (72.19Z)
- Sector
- Scientific research and development
- Headcount
- Headcount unknown
- Created
- 18 Aug 1983
- Establishments
- 2
Establishments
-
43350994000014 34000 MONTPELLIER
Financial strength
Financial score
Cannot be computed, not enough data
Confidence: low
formula fin-1.0
Legal score
80 / 100 A
Confidence: high
- No insolvency proceedings
- 40.0 out of 40
- Currently trading
- 20.0 out of 20
- Age (43.2 years)
- 20.0 out of 20
- Accounts filed recently
- 0.0 out of 20
formula leg-1.0
These scores are computed by us from public data, using a published formula. They are not advice, not a guarantee, not a credit decision, and they do not replace a review of the accounts. See how it is calculated
Explore similar companies
Frequently asked questions about ASS DEV.TECH.ADMIN.MEDICAMENT.CONTINUE
- What is the SIREN number of ASS DEV.TECH.ADMIN.MEDICAMENT.CONTINUE?
- The SIREN number of ASS DEV.TECH.ADMIN.MEDICAMENT.CONTINUE is 433509940. Its intra-community VAT number is FR04433509940.
- Where is the head office of ASS DEV.TECH.ADMIN.MEDICAMENT.CONTINUE?
- Head office address: 26 COURS GAMBETTA, 34000 MONTPELLIER.
- When was ASS DEV.TECH.ADMIN.MEDICAMENT.CONTINUE founded?
- ASS DEV.TECH.ADMIN.MEDICAMENT.CONTINUE was founded on 18 Aug 1983.
- What does ASS DEV.TECH.ADMIN.MEDICAMENT.CONTINUE do?
- Its declared main activity is: Other research and experimental development on natural sciences and engineering (NAF code 72.19Z).
- Is ASS DEV.TECH.ADMIN.MEDICAMENT.CONTINUE subject to insolvency proceedings?
- No ongoing insolvency proceedings are published in the BODACC for this company.